Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy [Melanoma]
Conclusion No survival benefit for adjuvant HDI in patients with a single positive SLN was found. Among patients with tumor-negative SLN by conventional pathology but with melanoma detected in the SLN by RT-PCR, there was no OS benefit for CLND or CLND+HDI. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: McMasters, Egger, Edwards, Ross, Reintgen, Noyes, Martin, Goydos, Beitsch, Urist, Ariyan, Sussman, Davidson, Gershenwald, Hagendoorn, Stromberg, Scoggins Tags: Surgery, Chemotherapy Melanoma Source Type: research

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection [Breast Cancer]
Conclusion Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and improves pathologic evaluation for residual nodal disease after chemotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Caudle, Yang, Krishnamurthy, Mittendorf, Black, Gilcrease, Bedrosian, Hobbs, DeSnyder, Hwang, Adrada, Shaitelman, Chavez-MacGregor, Smith, Candelaria, Babiera, Dogan, Santiago, Hunt, Kuerer Tags: Diagnosis & Staging, Surgery, Chemotherapy, Surgical Oncology Breast Cancer Source Type: research

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario [Breast Cancer]
Purpose To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort. Patients and Methods Patients with axillary node-negative or nodal micrometastases, estrogen receptor–positive, and human epidermal growth factor receptor 2–negative breast cancer being considered for chemotherapy were eligible. All cancer treatment centers in Ontario, Canada, participated. Oncologists made a preliminary recommendation for endocrine therapy with or without chemotherapy on the basis of Adjuvant! Online (AOL) risk estimation. Patients were asked for their preference regarding chemotherapy. Afte...
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Levine, Julian, Bedard, Eisen, Trudeau, Higgins, Bordeleau, Pritchard Tags: Chemotherapy, Quality of Care Breast Cancer Source Type: research

Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion Patients with pT1-2N0M0 SCLC treated with surgical resection alone have worse outcomes than those who undergo resection with adjuvant chemotherapy alone or chemotherapy with cranial irradiation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Yang, Chan, Speicher, Gulack, Wang, Hartwig, Onaitis, Tong, DAmico, Berry, Harpole Tags: Small Cell, Surgery, Radiation, Chemotherapy, Combined Modality Thoracic Oncology Source Type: research

Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies [Pediatric Oncology]
Conclusion Survival in pediatric HCC is more likely when complete tumor resection can be achieved. Intensification of platinum agents in the S2 and S3 trials has not resulted in improved survival. New treatment approaches in pediatric HCC should be postulated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Murawski, Weeda, Maibach, Morland, Roebuck, Zimmerman, Casanova, Perilongo, Laithier, Kebudi, Scopinaro, Shun, Brichard, de Camargo, Childs, Aronson, Czauderna Tags: Surgery, Chemotherapy, Long Term Survival & Late Effects, Hepatic Tumors Pediatric Oncology Source Type: research

Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors [Pediatric Oncology]
Conclusion PBRT was not associated with IQ decline or impairment, yet IQ slopes did not differ between the PBRT and XRT groups. It remains unclear if PBRT results in clinically meaningful cognitive sparing that significantly exceeds that of modern XRT protocols. Additional long-term data are needed to fully understand the neurocognitive impact of PBRT in survivors of pediatric brain tumors. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Kahalley, Ris, Grosshans, Okcu, Paulino, Chintagumpala, Moore, Guffey, Minard, Stancel, Mahajan Tags: Long Term Survival & Late Effects, CNS Tumors, Radiation Oncology Pediatric Oncology Source Type: research

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial [Rapid Communication]
Conclusion Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Piccart-Gebhart, Holmes, Baselga, de Azambuja, Dueck, Viale, Zujewski, Goldhirsch, Armour, Pritchard, McCullough, Dolci, McFadden, Holmes, Tonghua, Eidtmann, Dinh, Di Cosimo, Harbeck, Tjulandin, Im, Huang, Dieras, Hillman, Wolff, Jackisch, Lang, Untch, Sm Tags: Combined Modality, Rapid Communications Source Type: research

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Dang, Yu, Jones, Liu, Steingart, Argolo, Norton, Hudis Tags: Chemotherapy, Quality of Care COMMENTS AND CONTROVERSIES Source Type: research

Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Pietanza Tags: Small Cell, Combined Modality EDITORIALS Source Type: research

Proton Beam Radiation Therapy: The Future May Prove Brighter for Pediatric Patients With Brain Tumors [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Sands Tags: Long Term Survival & Late Effects, CNS Tumors, Outcomes Research, Radiation Oncology EDITORIALS Source Type: research

Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Sledge Tags: Combined Modality EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Kumar, Le Tags: Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Lee, Ruland, LeBoeuf, Wen, Santagata Tags: Brain Tumors, Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research

Concurrent Disseminated Nocardiosis and GI Mucormycosis in a Stem-Cell Transplantation Recipient [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Lim, Alker, Califano, Trembath, Alby, Gilligan, Jamieson, Serody, Shea Tags: Lymphoma DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to A. Indini et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Horvat, Adel, Dang, Momtaz, Postow, Callahan, Carvajal, Dickson, DAngelo, Woo, Panageas, Wolchok, Chapman Tags: CORRESPONDENCE Source Type: research

Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Indini, Di Nicola, Del Vecchio, De Braud Tags: CORRESPONDENCE Source Type: research

Reply to G.B. Holt [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Wright, Cronin, OMalley Tags: CORRESPONDENCE Source Type: research

Potential Simpson's Paradox in Multicenter Study of Intraperitoneal Chemotherapy for Ovarian Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Holt Tags: CORRESPONDENCE Source Type: research

Reply to L.A. Newman [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Elkin, Hudis Tags: CORRESPONDENCE Source Type: research

Parsing the Etiology of Breast Cancer Disparities [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Newman Tags: CORRESPONDENCE Source Type: research

You Have Seen Her Before [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Barot Tags: End of life issues, Ethics and legal issues, All Art of Oncology Articles Source Type: research

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology [ASCO SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Dizon, Krilov, Cohen, Gangadhar, Ganz, Hensing, Hunger, Krishnamurthi, Lassman, Markham, Mayer, Neuss, Pal, Richardson, Schilsky, Schwartz, Spriggs, Villalona-Calero, Villani, Masters Tags: Combined Modality, Hormonal Therapy, Leukemia, ASCO Guidelines, Translational Oncology, Surgery, Combined Modality, Radiation, Acute Lymphoblastic Leukemia ASCO SPECIAL ARTICLE Source Type: research

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer [Health Services and Outcomes]
Conclusion Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality. Further research is needed to understand the process by which extreme financial distress influences survival after cancer diagnosis and to find strategies that could mitigate this risk. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Ramsey, Bansal, Fedorenko, Blough, Overstreet, Shankaran, Newcomb Tags: Risk factors Health Services and Outcomes Source Type: research

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [Hematologic Malignancy]
Conclusion First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Amadori, Suciu, Selleslag, Aversa, Gaidano, Musso, Annino, Venditti, Voso, Mazzone, Magro, De Fabritiis, Muus, Alimena, Mancini, Hagemeijer, Paoloni, Vignetti, Fazi, Meert, Ramadan, Willemze, de Witte, Baron Tags: Chemotherapy Hematologic Malignancy Source Type: research

Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States [Epidemiology]
Purpose To compare incidence and survival of peripheral T-cell lymphoma (PTCL) subtypes among US racial/ethnic groups. Methods Patients with PTCL (age ≥ 15 years; 2000 to 2012) were identified in the Surveillance, Epidemiology, and End Results (SEER) registries. Race/ethnicity was categorized as non-Hispanic white, black, Asian/Pacific Islander, Hispanic white, or American Indian/Alaskan native. Age-standardized annual incidence rates and incidence rate ratios were estimated with 95% CIs, and case-case odds ratios were estimated by race/ethnicity using polytomous regression. Survival was estimated from SEER follow-up d...
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Adams, Newcomb, Shustov Tags: Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer [Thoracic Oncology]
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin and TRT followed by nonpemetrexed doublet consolidation therapy. Patients and Methods Patients with stage IIIA/B unresectable nonsquamous non–small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etop...
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Senan, Brade, Wang, Vansteenkiste, Dakhil, Biesma, Martinez Aguillo, Aerts, Govindan, Rubio-Viqueira, Lewanski, Gandara, Choy, Mok, Hossain, Iscoe, Treat, Koustenis, San Antonio, Chouaki, Vokes Tags: Radiation, Chemotherapy, Combined Modality Thoracic Oncology Source Type: research

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases [Breast Cancer]
Conclusion Although neratinib had low activity and did not meet our threshold for success, 12.5% of patients received six or more cycles. Studies combining neratinib with chemotherapy in patients with CNS disease are ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Freedman, Gelman, Wefel, Melisko, Hess, Connolly, Van Poznak, Niravath, Puhalla, Ibrahim, Blackwell, Moy, Herold, Liu, Lowe, Agar, Ryabin, Farooq, Lawler, Rimawi, Krop, Wolff, Winer, Lin Tags: Chemotherapy Breast Cancer Source Type: research

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer [Breast Cancer]
We examined the prognostic and predictive value of serum human epidermal growth factor 2 (HER2) extracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data from three randomized trials. Patients and Methods We analyzed sHER2 and tissue HER2 (tHER2) data from 1,902 patients (84%) who were randomly assigned to receive lapatinib or control in the trials EGF30001, EGF30008, and EGF100151. Cox regression analyses were performed to correlate both biomarkers with progression-free survival (PFS) and overall survival (OS). Results Median sHER2 levels were 25.1 and 10.1 ng/mL in tHER2-amp...
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Lee, Davies, Gebski, Lord, Di Leo, Johnston, Geyer, Cameron, Press, Ellis, Loi, Marschner, Simes, de Souza Tags: Translational Oncology, Cancer Biomarkers Breast Cancer Source Type: research

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V [Breast Cancer]
Purpose Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer. Patients and Methods International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 and 1985. Annualized hazards were estimated for breast cancer–free interval (primary end point), disease-free survival, and overall survival. Results For the entire group, the annualized hazard of recurrence was highest du...
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Colleoni, Sun, Price, Karlsson, Forbes, Thurlimann, Gianni, Castiglione, Gelber, Coates, Goldhirsch Tags: Chemotherapy, Hormonal Therapy Breast Cancer Source Type: research

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy [Pediatric Oncology]
Conclusion CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Vora, Andreano, Pui, Hunger, Schrappe, Moericke, Biondi, Escherich, Silverman, Goulden, Taskinen, Pieters, Horibe, Devidas, Locatelli, Valsecchi Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research

Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study [Pediatric Oncology]
Purpose Little is known about the breast cancer risk among childhood cancer survivors who did not receive chest radiotherapy. We sought to determine the magnitude of risk and associated risk factors for breast cancer among these women. Patients and Methods We evaluated cumulative breast cancer risk in 3,768 female childhood cancer survivors without a history of chest radiotherapy who were participants in the Childhood Cancer Survivor Study. Results With median follow up of 25.5 years (range, 8 to 39 years), 47 women developed breast cancer at a median age of 38.0 years (range, 22 to 47 years) and median of 24.0 years (ra...
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Henderson, Moskowitz, Chou, Bradbury, Neglia, Dang, Onel, Novetsky Friedman, Bhatia, Strong, Stovall, Kenney, Barnea, Lorenzi, Hammond, Leisenring, Robison, Armstrong, Diller, Oeffinger Tags: Epidemiology, Long Term Survival & Late Effects, Outcomes Research Pediatric Oncology Source Type: research

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [Rapid Communication]
Conclusion THP in patients with metastatic HER2-positive breast cancer is unlikely to be cost effective in the United States. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Durkee, Qian, Pollom, King, Dudley, Shaffer, Chang, Gibbs, Goldhaber-Fiebert, Horst Tags: Chemotherapy, Cost Effectiveness, Outcomes Research, Cost of Cancer Care, Rapid Communications Source Type: research

Clinically Significant Germline Mutations in Cancer-Causing Genes Identified Through Research Studies Should Be Offered to Research Participants by Genetic Counselors [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Forrest, Young Tags: Risk factors, Gene Expression and Profiling, Oncogenes COMMENTS AND CONTROVERSIES Source Type: research

Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Bergh, Pritchard, Cameron Tags: Chemotherapy, Combined Modality, Hormonal Therapy EDITORIALS Source Type: research

Anthracyclines and Alkylating Agents: New Risk Factors for Breast Cancer in Childhood Cancer Survivors? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: van Leeuwen, Ronckers Tags: Long Term Survival & Late Effects EDITORIALS Source Type: research

Walking the Tightrope Between Treatment Efficacy and Price [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Bach Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Liver Failure After Abdominal Irradiation: Identifying the Right Suspects [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Dal Pra, Berlin, Kumareswaran, Schattner, Craig, Wong, Hodgson, Fischer, Bristow, Dawson Tags: Supportive Care, Radiation, Combined Modality, Translational Oncology, Combined Modality, Translational Oncology, Radiation Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Shuch, Agochukwu, Ricketts, Vocke, Gautam, Merino, Linehan, Srinivasan Tags: DIAGNOSIS IN ONCOLOGY Source Type: research

Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Akthar, Golden, Nanda, Sharma, Te, Reddy, Zhang, Malik Tags: Radiation, Chemotherapy, Combined Modality, Radiation Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to M.P. Decatris et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Hyman, Solit, Iasonos Tags: CORRESPONDENCE Source Type: research

Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Decatris, Farrugia, OByrne Tags: CORRESPONDENCE Source Type: research

Reply to F.M. Muggia [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Bookman, Brady Tags: CORRESPONDENCE Source Type: research

Intraperitoneal Therapy for Ovarian Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Muggia Tags: CORRESPONDENCE Source Type: research

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer [UNDERSTANDING THE PATHWAY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Awad Tags: Understanding the Pathway Source Type: research